Abstract
Objective
Differential diagnosis between Parkinson’s disease (PD) and other Parkinsonism using clinical criteria or imaging methods is often difficult. The purpose of this study is to systematically review and meta-analyze published data about the diagnostic performance of myocardial innervation imaging using 123I-metaiodobenzylguanidine (MIBG) scintigraphy in differential diagnosis between PD and other Parkinsonism.
Methods
A comprehensive computer literature search of studies published through March 2011 regarding MIBG scintigraphy in patients with PD and other Parkinsonism was performed in PubMed/MEDLINE and Embase databases. Only studies in which MIBG scintigraphy was performed for differential diagnosis between PD and other Parkinsonism were selected. Pooled sensitivity, pooled specificity and area under the ROC curve were calculated to measure the accuracy of MIBG scintigraphy in differential diagnosis between PD and other Parkinsonism.
Results
Nineteen studies comprising 1,972 patients (1,076 patients with PD, 117 patients with other Lewy body diseases and 779 patients with other diseases) were included in this meta-analysis. The pooled sensitivity of MIBG scintigraphy in detecting PD was 88% (95% CI 86–90%); the pooled specificity of MIBG scintigraphy in discriminating between PD and other Parkinsonism was 85% (95% CI 81–88%). The area under the ROC curve was 0.93.
Conclusions
In patients with clinically suspected PD, myocardial innervation imaging demonstrated high sensitivity and specificity. MIBG scintigraphy is an accurate test in this setting. Nevertheless, possible causes of false-negative and false-positive results should be kept in mind when interpreting the scintigraphic results.
Similar content being viewed by others
References
Jost WH, Del Tredici K, Landvogt C, Braune S (2010) Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes. Neurodegener Dis 7:341–347
Treglia G, Cason E, Gabellini A, Giordano A, Fagioli G (2010) Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci 31:417–422
Yamashina S, Yamazaki J (2007) Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 34:939–950
Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S (2008) Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 52:378–387
Rascol O, Schelosky L (2009) 123I-Metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord 24(Suppl 2):732–741
Treglia G, Cason E (2010) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. doi:10.1111/j.1552-6569.2010.00532.x (epub ahead of print)
Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 105:341–350
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31
Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH (1999) Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53:1020–1025
Salsone M, Bagnato A, Novellino F, Cascini GL, Paglionico S, Cipullo S, Morelli M, Pugliese P, Nicoletti G, Messina D, Condino F, Arabia G, Morgante L, Quattrone A (2009) Cardiac MIBG scintigraphy in primary progressive freezing gait. Parkinsonism Relat Disord 15:365–369
Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, Hasegawa Y, Takahashi A (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53:230–234
Druschky A, Hilz MJ, Platsch G, Radespiel-Tröger M, Druschky K, Kuwert T, Neundörfer B (2000) Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3–12
Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Taki K, Takahashi A (2003) [123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson’s disease. Intern Med 42:127–128
Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM (2003) Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 18:890–897
Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, Saiki M, Kaito M, Higashi K, Taki S, Kakeshita K, Fujino S, Miaki M (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220:105–111
Matsui H, Udaka F, Oda M, Kubori T, Nishinaka K, Kameyama M (2005) Metaiodobenzylguanidine (MIBG) scintigraphy at various parts of the body in Parkinson’’s disease and multiple system atrophy. Auton Neurosci 119:56–60
Lee PH, Kim JS, Shin DH, Yoon SN, Huh K (2006) Cardiac 123I-MIBG scintigraphy in patients with drug induced Parkinsonism. J Neurol Neurosurg Psychiatry 77:372–374
Shin DH, Lee PH, Bang OY, Joo IS, Huh K (2006) Clinical implications of cardiac-MIBG SPECT in the differentiation of Parkinsonian syndromes. J Clin Neurol 2:51–57
Lee PH, Yeo SH, Kim HJ, Youm HY (2006) Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson’s disease and multiple system atrophy. Mov Disord 21:1975–1977
Lee PH, Yeo SH, Yong SW, Kim YJ (2007) Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced Parkinsonism. J Neurol Neurosurg Psychiatry 78:1250–1252
Yamashita F, Hirayama M, Nakamura T, Takamori M, Hori N, Uchida K, Hama T, Sobue G (2010) Pupillary autonomic dysfunction in multiple system atrophy and Parkinson’s disease: an assessment by eye-drop tests. Clin Auton Res 20:191–197
Marini C, Bandettini di Poggio M, Pomposelli E, Marchese R, Nobili F, Morbelli SD, Villa G, Abbruzzese G, Sambuceti G (2010) Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. Clin Nucl Med 35:311–316
Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T, Haruta H (2011) Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord. doi:10.1016/jparkreldis.2011.02.001 (epub ahead of print)
Fröhlich I, Pilloy W, Vaillant M, Diederich NJ (2010) Myocardial MIBG scintigraphy: a useful clinical tool? A retrospective study in 50 Parkinsonian patients. Neurol Sci 31:403–406
Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, Mizusawa H, Ishii K (2010) Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 37:3–11
Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH (2009) MIBG scintigraphy for differentiating Parkinson’s disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 24:1650–1655
Novellino F, Arabia G, Bagnato A, Cascini GL, Salsone M, Nicoletti G, Messina D, Morelli M, Paglionico S, Giofrè L, Restuccia A, Torchia G, Condino F, Quattrone A (2009) Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. Mov Disord 24:2242–2248
Sawada H, Oeda T, Yamamoto K, Kitagawa N, Mizuta E, Hosokawa R, Ohba M, Nishio R, Yamakawa K, Takeuchi H, Shimohama S, Takahashi R, Kawamura T (2009) Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 16:174–182
Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K (2008) 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31:717–723
Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Tamura S, Nakazato M, Yamashita S, Arita H, Nishii R, Kawai K (2008) Usefulness of rCBF analysis in diagnosing Parkinson’s disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 22:557–564
Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, Mueller J, Sawires M, Scherfler C, Schocke MF, Donnemilier E, Virgolini I, Wenning GK, Poewe W (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22:1771–1776
Kashihara K, Ohno M, Kawada S, Okumura Y (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med 47:1099–1101
Kim JS, Lee PH, Lee KS, Park JW, Kim YI, Chung YA, Kim SH, Kim SH, Kim J, Choi YY, Kim HT (2006) Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. Mov Disord 21:1990–1994
Lee PH, Kim JW, Bang OY, Joo IS, Yoon SN, Huh K (2006) Cardiac 123I-MIBG scintigraphy in patients with essential tremor. Mov Disord 21:1235–1238
Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251
Reinhardt MJ, Jüngling FD, Krause TM, Braune S (2000) Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 27:595–600
Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, Matsuo H, Watanabe S, Satomi K (2000) Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 284:44–45
Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566–573
Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194
Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, Takashima H, Tsujihata M (1999) Loss of 123I-MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 40:371–375
Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL (2008) Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 29:1147–1159
King AE, Mintz J, Royall DR (2011) Meta-analysis of (123) I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. doi:10.1002/mds.23659
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513–521
Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H (2007) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113:81–86
Sakata K, Iida K, Mochizuki N, Ito M, Nakaya Y (2009) Physiological changes in human cardiac sympathetic innervation and activity assessed by 123I-Metaiodobenzylguanidine (MIBG) imaging. Circ J 73:310–315
Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of Parkinsonian syndromes. Clin Auton Res 11:351–355
Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, Somsen GA, Unlu M, Verberne HJ, EANM Cardiovascular Committee; European Council of Nuclear Cardiology (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812
Muxí A, Paredes P, Navales I, Valldeoriola F, Gaig C, Lomeña F, de la Cerda A, Solà O, Domenech B, Tolosa E, Pons F (2011) Diagnostic cutoff points for (123)I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson’s disease. Eur J Nucl Med Mol Imaging 38:1139–1146
Acknowledgement
The Authors are grateful to Professor Guido Galli for his statistical support and Ms. Barbara Muoio for her technical support.
Conflicts of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Treglia, G., Cason, E., Stefanelli, A. et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 22, 43–55 (2012). https://doi.org/10.1007/s10286-011-0135-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10286-011-0135-5